Prospective Multicentre Study of the Use of Ketamine in the Treatment of Refractory Chronic Pain in the French CLCC

CompletedOBSERVATIONAL
Enrollment

81

Participants

Timeline

Start Date

February 2, 2021

Primary Completion Date

February 6, 2023

Study Completion Date

March 9, 2023

Conditions
CancerChronic PainNeuropathic PainOpioid Use
Interventions
DRUG

Ketamine use in CLCC sites (indication and administration protocol)

"Collection of information concerning Ketamine use by French CLCCs pain teams (first prescription):~1. Indications : analgesic treatment of cancer chronic pain, analgesic treatment for a post-cancer treatment chronic pain, help for withdrawal from opioid treatment prescribed for a chronic cancer pain~2. Administration protocol: route, posology, duration, administration sequence, premedication~3. Antalgic efficacy~4. Tolerance profile~5. Quality of life, anxiety and depression evaluations"

Trial Locations (12)

13273

Institut Paoli Calmettes, Marseille

31059

Institut Universitaire du Cancer (IUCT), Toulouse

33076

Institut Bergonié, Bordeaux

34298

Institut de Cancérologie de Montpellier, Montpellier

35042

Centre Eugène Marquis, Rennes

51056

Institut Godinot, Reims

54519

Institut de Cancérologie de Lorraine Alexis Vautrin, Vandœuvre-lès-Nancy

63011

Centre Jean Perrin, Clermont-Ferrand

69008

Centre Leon Berard, Lyon

75005

Institut Curie, Paris

94805

Institut Gustave Roussy, Villejuif

Unknown

Centre François Baclesse, Caen

All Listed Sponsors
lead

Centre Leon Berard

OTHER

NCT04459234 - Prospective Multicentre Study of the Use of Ketamine in the Treatment of Refractory Chronic Pain in the French CLCC | Biotech Hunter | Biotech Hunter